Amgen closed its $3.7 billion purchase of ChemoCentryx Thursday morning.
The deal for the company, which is focused on developing orally administered treatments for autoimmune diseases, inflammatory disorders and cancer, was first announced in August.
The focal point of the transaction is Tavneos, a first-in-class treatment for ANCA-associated vasculitis. At the time the deal was announced, Amgen CEO Robert Bradway called it a “compelling opportunity” for the company to extend its inflammation and nephrology portfolio.
In addition to Tavneos, Amgen adds three early-stage drug candidates to its roster as well.
“We look forward to welcoming the dedicated professionals from ChemoCentryx who share our passion for advancing innovation that makes a difference for patients. Together, we aim to serve more patients affected by serious diseases,” Bradway said in a statement Thursday.
The ChemoCentryx deal closed two weeks before Amgen is scheduled to host its Q3 earnings call.